- The disease
- Body composition analysis refers to the measurement of lean muscle mass, fat tissue, and body fluid levels in a patient or subject. Accurate tracking of these parameters is relevant across a range of clinical settings, including cancer treatment monitoring, kidney disease management via haemodialysis, and lymphoedema surveillance in breast cancer patients. Changes in lean muscle and fluid distribution can indicate disease progression or treatment response. These measurements have traditionally been made using dual-energy X-ray absorptiometry (DXA), a specialised imaging technology typically available only in hospital or radiology settings.
- What the asset is trying to do
- SOZO is a cleared medical device that uses bioimpedance spectroscopy (BIS), a technique that passes a small electrical current through the body to measure resistance in tissues. This resistance data is used to estimate lean muscle mass, fat, and fluid volumes across different body segments. ImpediMed states that the device's segmental BIS measurements correlate highly with DXA readings. Unlike DXA, SOZO does not use ionising radiation and is a point-of-care device, meaning it can be used outside of a radiology suite.
- What the trial is measuring, and why it matters
- Clinical studies involving the SOZO device have used it alongside DXA scanning to assess how closely the two methods agree on body composition measurements in cancer patients (per ClinicalTrials.gov NCT03690401 and NCT03784911). A separate study is examining its use for fluid monitoring in haemodialysis patients with chronic kidney failure (per ClinicalTrials.gov NCT05381961). The PREVENT study (NCT02167659) and the Subclinical Lymphedema Treatment Study (NCT03292198) evaluated BIS-guided monitoring and intervention in breast cancer-related lymphoedema. These studies measure outcomes such as agreement between device readings and reference standards, and clinical outcomes following BIS-guided treatment decisions.
- Efficacy benchmarks in this setting
- In the context of lymphoedema detection, the PREVENT trial (NCT02167659) enrolled 1,201 patients and has been previously reported in peer-reviewed literature; analysts should consult published results directly for cited outcome figures. For body composition assessment, DXA is considered a reference standard against which BIS devices are compared; specific agreement statistics from the SOZO versus DXA studies (NCT03690401, NCT03784911) are available in published or registry-reported results and should be cited directly from those sources. Because SOZO is a cleared diagnostic device and not an investigational therapeutic, its clinical study data is not directly analogous to drug efficacy readouts; the comparisons relevant here are device-versus-reference-standard agreement metrics, not response rates or survival figures.